Health Care & Life Sciences » Pharmaceuticals | Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc. Cl A | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
197,602.00
248,334.00
439,394.00
305,216.00
221,416.00
174,422
Total Accounts Receivable
3,213.00
25,839.00
54,518.00
64,854.00
82,157.00
80,950
Inventories
22,145.00
4,954.00
-
1,081.00
735.00
-
Other Current Assets
6,168.00
10,603.00
6,293.00
9,030.00
7,288.00
11,063
Total Current Assets
229,128.00
289,730.00
500,205.00
380,181.00
311,596.00
266,435
Net Property, Plant & Equipment
37,376.00
29,826.00
21,075.00
20,512.00
17,274.00
17,270
Total Investments and Advances
8,147.00
8,147.00
95,213.00
140,768.00
115,244.00
47,446
Intangible Assets
-
-
-
166,904.00
160,690.00
785
Other Assets
4,311.00
5,810.00
2,628.00
1,456.00
870.00
114
Total Assets
278,962.00
333,513.00
619,121.00
709,821.00
605,674.00
332,050
ST Debt & Current Portion LT Debt
1,139.00
12,410.00
27,595.00
6,227.00
4,077.00
Accounts Payable
10,187.00
9,762.00
8,589.00
17,703.00
15,958.00
Other Current Liabilities
29,714.00
38,369.00
40,281.00
67,201.00
45,992.00
Total Current Liabilities
41,040.00
60,541.00
76,465.00
91,131.00
66,027.00
Long-Term Debt
177,806.00
164,909.00
353,890.00
366,574.00
396,091.00
Provision for Risks & Charges
-
-
-
63,416.00
31,011.00
Other Liabilities
21,891.00
19,511.00
93,641.00
121,984.00
102,697.00
Total Liabilities
240,737.00
244,961.00
523,996.00
643,105.00
595,826.00
Common Equity (Total)
38,225.00
88,552.00
95,125.00
66,716.00
9,848.00
Total Shareholders' Equity
38,225.00
88,552.00
95,125.00
66,716.00
9,848.00
Total Equity
38,225.00
88,552.00
95,125.00
66,716.00
9,848.00
Liabilities & Shareholders' Equity
278,962.00
333,513.00
619,121.00
709,821.00
605,674.00

About Ironwood Pharmaceuticals

View Profile
Address
301 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.ironwoodpharma.com
Updated 07/08/2019
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M.